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Abstract
Background. Variability in standard-of-care classifications precludes accurate predictions of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection of patients who would benefit
from adjuvant radiotherapy to delay recurrence. We aimed to develop an individualized prediction model of early
recurrence risk combining clinical and molecular factors in meningioma.
Methods. DNA methylation profiles of clinically annotated tumor samples across multiple institutions were used
to develop a methylome model of 5-year recurrence-free survival (RFS). Subsequently, a 5-year meningioma recurrence score was generated using a nomogram that integrated the methylome model with established prognostic
clinical factors. Performance of both models was evaluated and compared with standard-of-care models using
multiple independent cohorts.

Published by Oxford University Press on behalf of the Society for Neuro-Oncology 2019.
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Key Points
1. Combining DNA methylation with clinical factors results in reliable individualized
estimations of recurrence risk.
2. Individualized recurrence risk can be used to guide decisions for postoperative
therapeutic interventions.

Importance of the Study
Our work is the first to demonstrate the transformative utility of integrating clinical and molecular factors
for use beyond simple classification into the realm of
individualized prognostication for any brain tumor. Using
our developed and validated tools that are publicly
available, clinicians will be able combine clinical and

Meningiomas are the most common primary intracranial
tumor. They account for 37% of all central nervous system
tumors and are continuing to increase in incidence with the
aging population.1 They result in significant neurological morbidity and loss of quality of life by exerting mass effect on critical adjacent brain regions.1 The current standard of care for
nearly all patients with symptomatic meningiomas includes
gross total tumor resection with removal of involved dura and
bone when possible.2 However, despite radical surgical resection, approximately 20% of meningiomas display aggressive
behavior, with early tumor recurrence resulting in a clinical
course of repetitive disease- and treatment-related morbidity.
Radiation therapy can be used to provide disease control as
an adjunct to surgery for a subset of tumors.3,4 However, radiotherapy can often result in adverse radiation effects that
lead to considerable morbidity and neurological dysfunction
long term, precluding universal use in all patients.5 One of the
greatest clinical challenges faced by clinicians is the inability
to predict early tumor recurrence at an individual patient level,
which limits the appropriate selection of patients who would
benefit from adjuvant radiation therapy.
To date, the most reliable clinical factors associated with
recurrence in meningiomas have been the World Health
Organization (WHO) grade of the tumor and extent of tumor
resection at surgery.2,6 Although both are crudely associated with recurrence rates on a population level, they are

molecular factors to determine an individualized probability of recurrence for patients with meningiomas. This
represents a major advance in the field of personalized
medicine for neuro-oncology, and the use of this tool can
help clinicians overcome one of the most challenging limitations we face when treating patients with meningiomas.

challenged with interrater variability of grading and considerable within-grade variation of recurrence risk for individual patients.2,6 In the past decade, several studies have
focused on molecular profiling of meningiomas to refine
biological subgroups.7–13 With the exception of mutations
in BAP1 (breast cancer associated protein 1) and telomerase reverse transcriptase (TERT) promoter, each of which
occurs rarely in these tumors, the mutations identified in
meningioma have not been shown to be tightly correlated
to patient outcome with current standard of care.7–10 We
and others have independently shown that global DNA
methylation profiling reveals robust methylome-based
meningioma subtypes; however, the clinical translation of
this to predict recurrence risk for individual patients has
not been demonstrated to date.
To examine whether methylation profiles can be defined
and validated for clinical utility, we aimed to develop and
validate a methylome-based predictor of early meningioma
recurrence that could be combined with established prognostic clinical factors to individualize decisions regarding the
need for postoperative therapeutic interventions—in particular, whether to treat patients with adjuvant radiation therapy
versus observation alone. Our work is the first in neurooncology to demonstrate the transformative utility of integrating clinical and molecular factors for use beyond simple
classification into the realm of individualized prognostication.

Downloaded from https://academic.oup.com/neuro-oncology/article/21/7/901/5510481 by Henry Ford Hospital - Sladen Library user on 14 March 2022

Results. The methylome-based predictor of 5-year RFS performed favorably compared with a grade-based
predictor when tested using the 3 validation cohorts (ΔAUC = 0.10, 95% CI: 0.03–0.018) and was independently associated with RFS after adjusting for histopathologic grade, extent of resection, and burden of copy
number alterations (hazard ratio 3.6, 95% CI: 1.8–7.2, P < 0.001). A nomogram combining the methylome
predictor with clinical factors demonstrated greater discrimination than a nomogram using clinical factors
alone in 2 independent validation cohorts (ΔAUC = 0.25, 95% CI: 0.22–0.27) and resulted in 2 groups with
distinct recurrence patterns (hazard ratio 7.7, 95% CI: 5.3–11.1, P < 0.001) with clinical implications.
Conclusions. The models developed and validated in this study provide important prognostic information
not captured by previously established clinical and molecular factors which could be used to individualize
decisions regarding postoperative therapeutic interventions, in particular whether to treat patients with
adjuvant radiotherapy versus observation alone.
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Study Design and Data Sources

Definitions
Hematoxylin and eosin (H&E) slides for each patient were reviewed for meningioma diagnosis, and
WHO grading was performed according to the current
WHO 2016 criteria at local institutions by experienced
neuropathologists. Tumor recurrence and time to recurrence were the primary outcomes of interest and
were collected locally for each sample as previously
described.11,12 Briefly, recurrence was defined as tumor
growth following gross total resection or tumor progression following subtotal resection. Time to recurrence
was determined by reviewing postoperative imaging
and calculating the duration from the date of surgery to
first postoperative imaging documenting tumor recurrence in concordance with documentation in the medical charts. The extent of resection (Simpson grade2) was
determined based on the surgeon’s operative report in
correlation with postoperative cranial imaging.

Generation of a Meningioma Recurrence Score
To create a contemporary meningioma recurrence score
that could be utilized by clinicians to predict early risk of
recurrence for individual patients, we generated a nomogram based on a Cox model that incorporated the
methylome-based predictor, WHO grade, and extent of resection using samples from the training cohort and second
validation cohort to predict 5-year RFS. Both the training
cohort and second validation cohort were used to train this
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This multicenter retrospective study was carried out
in accordance with individual institutional ethics and
review board guidelines and comprised a total of 486
patients with clinically annotated and available meningioma samples. Institutional waivers of informed
consent were obtained due to minimal patient risk associated with this study. Two-hundred and eighty-two (N
= 282) fresh frozen or formalin fixed paraffin embedded
(FFPE) meningioma tumor samples from multiple
institutions (N = 76 from Princess Margaret Cancer
Research Centre; N = 206 from European centers, including University of Heidelberg, Goethe-University,
University of Tubingen, University Hospital Zurich, and
Medical University of Vienna) composed the discovery
cohort, which was split into a training cohort (81%, N
= 228 samples) and a first validation cohort (19%, N = 54
samples), each balanced for tumor grade, tissue type,
recurrence status, and time to recurrence. One hundred
and forty (N = 140) FFPE meningioma tumor samples
from a separate institution (The MD Anderson Cancer
Center) were used as a second validation cohort, and
N = 64 fresh frozen meningioma tumor samples from
2 other institutions were used as a third validation cohort (N = 46 from Princess Margaret Cancer Research
Centre; N = 18 from The Chinese University of Hong
Kong). The sample sets from Europe and MD Anderson
composed the subset of previously published samples
for which clinical data (recurrence-free survival [RFS],
WHO grade) were available. 11,12 Moreover, TERT promoter mutation status was available on a subset of
previously published European samples. 10,11 Gene expression analysis was performed on publicly available microarray data on 98 patients with meningiomas
of all grades (GSE16581 14 and GSE9438 15). The outline for the overall study design is demonstrated in
Supplementary Fig. 1

For DNA methylation and copy number analysis of the
samples, DNA was extracted from each tumor and DNA
methylation profiling was performed using Illumina 450k
HumanMethylation BeadChip or 850k EPIC arrays as per
manufacturer instructions at each institution. Raw data
files (*.idat) were imported, processed, and normalized
to integrate data from multiple generations of Infinium
methylation arrays. Copy number aberrations were
inferred from methylation array data,16 and burden of copy
number alterations was computed per sample as previously described.17 Probes that were common in both 450k
HumanMethylation Beadchip and 850k EPIC arrays were
selected as possible features for development of our predictor such that our predictor would be applicable to the
landscape of available technologies. We used a multistep strategy to select the probes to be used in the generation of our predictor (see Supplementary Methods and
Supplementary Fig. 2).
To develop the methylome-based predictor of early meningioma recurrence, we performed generalized boosted
regression modeling using the final selected probes in
samples from the training cohort to predict 5-year RFS.
Boosted regression modeling using WHO grade as the
sole feature in the training cohort was also performed and
tested in each validation cohort to compare methylationbased predictor performance with a standard-of-care
model. Performance of both models was assessed by
generating time-dependent receiver operating characteristic (ROC) curves and computing average areas under the
ROC curves (AUCs) for each validation cohort independently, along with their 95% confidence intervals using the
bootstrap resampling method with 10 000 resamples.18
Methylation probe annotation was performed using
the University of California Santa Cruz Genome Browse
(GRCh38/hg38 assembly). We used the Functional
Annotation Clustering algorithm19 of DAVID (Database
for Annotation, Visualization, and Integrated Discovery)19
Bioinformatics Resource 6.8 to identify redundant functional clusters represented by genes annotated with a
minimum of 5 probes (see Supplementary Fig. 3). Two
publicly available microarray datasets (GSE1658114 and
GSE943815) reporting on 22 486 genes for 98 patients with
meningiomas were pooled to correlate methylation data
with gene expression data as an exploratory analysis.
Further details regarding the steps for generation, validation, and characterization of the methylome predictor of
5-year RFS can be found in the Supplementary Methods.
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Statistical Analysis
Summary statistics are reported as counts (and
proportions) for categorical variables and median (and
range) for continuous variables, unless otherwise indicated. Cohort size was determined by availability of
samples. Statistical analyses were performed in consultation with 2 expert biostatisticians (L.P. and O.S.).
To investigate the clinical relevance of the methylomebased predictor and meningioma recurrence score,
distribution of survival times was performed using Kaplan–
Meier methods and compared across groups using logrank testing. The frequency of genome-wide copy number
alterations across groups was computed and plotted using
a custom algorithm. The performance of a methylomebased predictor was compared with a grade-based predictor by computing an average ΔAUC (AUCmethylome
− AUCgrade) and 95% CI from all bootstraps, and the performance of the meningioma recurrence score incorporating
the methylome predictor was compared with a nomogram
excluding the methylome predictor by computing average
ΔAUC (AUCcombined nomogram –AUCclinical only nomogram) and 95%
CI in similar fashion.
Hazard ratios (HRs), including 95% CIs, were calculated
based on univariable and multivariable Cox regression
modeling for the methylome-based predictor and other
covariates, including WHO grade, extent of resection, and
burden of copy number alterations. Proportional hazards
assumption was tested by computing Schoenfeld residuals
for each covariate, and testing was performed according
to Grambsch and Therneau21 (Supplementary Fig. 5 and
Supplementary Table 1). Martingale residuals were plotted
against methylation predictor probabilities to determine
appropriateness of linear modeling (Supplementary Fig. 6).
Sensitivity analyses evaluating the possible confounding
effects of TERT promoter mutations, receipt of adjuvant radiation therapy, and center effects were performed using
multivariable Cox regression in samples with available information. Comparison of proportions across groups was
completed using the χ2 test and Fisher’s exact test, where
appropriate.

Two-sided P-values are reported, and the threshold for
statistical significance was set a priori at α = 0.05. We used
R v3.3.1 for all statistical analyses, model generation, and
model validation.

Results
A set of 9529 probes were selected from an initial training
cohort, and generalized boosted regression modeling was
performed to develop a DNA methylation-based predictor
of 5-year recurrence risk in meningioma (Supplementary
Fig. 1). Three validation cohorts (Supplementary Table
2) were used to test the performance of the methylationbased predictor compared with a grade-based predictor.

Validation of a Methylome Predictor of Early
Meningioma Recurrence
The methylome-based predictor performed favorably
compared with the grade-based predictor at 5 years in
each of the 3 validation cohorts (Fig. 1), with substantial
statistical improvements in performance when tested in all
combined validation cohorts (ΔAUC = 0.10, 95% CI: 0.03–
0.18). When stratified by median, the 5-year methylome
predictor distinguished risk groups (lower and higher risk)
in all 3 validation cohorts (Fig. 2). Patients in the higher
risk group had a median RFS of 2.1 years, 8.1 years, and
4.2 years in the first, second, and third validation cohorts,
respectively, compared with patients in the lower risk
groups, which had median RFS of “unreached” in the
first and second validation cohorts and median RFS of
7.2 years in the third validation cohort (HR 8.1, 95% CI: 2.8–
23.8; HR 3.5, 95% CI: 1.8–6.6, and HR 2.0, 95% CI: 1.2–3.7,
respectively).
DNA copy number analysis demonstrated increased
frequency of copy number aberrations in the higher risk
groups by a high proportion of chromosomal deletions
in 1p, 4p, 6q, 10q, 14q, and 18q (Fig. 3). The total burden
of copy number alterations was also correlated with risk
groups, with greatest proportion of burden of copy number
alterations found in the higher risk groups in all 3 validation
cohorts (Supplementary Table 3). It is noteworthy that of all
patients with a high burden of copy number aberrations
from all 3 validation cohorts, only 12 patients (4.6%) were
in the lower risk group.
Multivariable Cox regression analysis demonstrated
that the 5-year methylome-based predictor was independently associated with RFS in samples from all validation
cohorts (HR 3.6, 95% CI: 1.8–7.2, P < 0.001) after controlling
for tumor grade, extent of resection, and burden of copy
number alterations (Supplementary Table 4). Sensitivity
analyses including receipt of adjuvant therapy, TERT promoter mutations, and center of treatment as covariates
did not alter this relationship and these covariates were
not independently associated with RFS (Supplementary
Tables 5–7).
Current clinical practice relies on histopathologic
grade to inform the decision of postsurgical management of meningioma. Patients with grade I tumors are
most commonly monitored with serial imaging after
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nomogram in order to increase the number of samples
available to capture the heterogeneity in the spectrum of
data available. This is important to note, as none of the
samples to train this model were used to assess model
performance on external validation. Global performance
of the meningioma recurrence was assessed by generating
time-dependent ROC curves and computing average AUC
for the first and third validation cohort independently,
along with their 95% CIs using the bootstrap resampling
method with 10 000 resamples.18,20 For comparison, a nomogram that incorporated only WHO grade and extent of
resection as the sole features was also developed in similar fashion. Internal validation using bootstrap resampling
of 10 000 resamples was also performed. Model calibration was assessed visually by plotting observed event
rates against nomogram predicted probabilities for 2 risk
groups. Detailed descriptions on nomogram calculations
and use are described in the Supplementary Methods and
Supplementary Fig. 4.
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First validation
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(95% CI
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Fig. 1 Comparison of grade-based and methylome-based RFS predictor performance. Data presented are time-dependent ROC curves and average AUC as well as ΔAUC (DAUC) with 95% CI using 10 000 bootstrap resampling validation approach for methylome-based and grade-based
predictors in the (A) first validation cohort, (B) second validation cohort, (C) third validation cohort, and (D) combined validation cohorts.
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Fig. 2 RFS analysis of the first validation cohort (A), second validation cohort (B), and (C) third validation cohort using the 5-year methylome-based
RFS predictor, based on separation into distinct risk groups by median.

surgery, while patients with grade II and III tumors are
considered for adjuvant therapy, such as radiation, to
prevent recurrence. There is, however, unexplained clinical variability in RFS within all grades of meningioma,
and we examined the use of the 5-year methylome predictor to address this issue. Among patients with WHO
grade II tumors in all validation cohorts, the median RFS
for the higher risk group was 2.6 years compared with
a median RFS of 8.4 years in the lower risk group (HR
2.8, 95% CI: 1.7–4.8, P < 0.001; Fig. 4B). Patients with
WHO grade I tumors in all validation cohorts also had
increased risk for recurrence in the higher risk group
(HR 2.9, 95% CI: 1.3–6.6, P = 0.006; Fig. 4A), with only
3 patients in the lower risk group recurring within the
first 5 years compared with 18 patients in the higher
risk group. Lastly, patients with WHO grade III tumors
from all validation cohorts had poor median RFS in the
higher risk group (1.3 y), compared with a median RFS
of 6.0 years in the lower risk group (HR 3.0, 95% CI: 1.4–
6.5, P = 0.004; Fig. 4C).

Characterization of Predictor
Cytosine-Phosphate-Guanine Sites
The selected 9529 probes used in our model make up only
1% of all probes included on the 850k Illumina Array. These
probes were enriched to be found in the promoter regions
(N = 3057, 32.1%) and located on cytosine-phosphateguanine (CpG) islands (N = 4633, 48.6%) compared with all
probes found on the 850k Illumina Array (29.6%, P < 0.001
and 18.0%, P < 0.001, respectively; Supplementary Table
8). Of the 9529 probes, only 1261 (13.2%) were “favorable,” associated with lower risk of recurrence when methylated (HR ranging from 0.002 to 0.38 on univariable Cox
regression with associated P < 0.001). The remaining 8237
(86.8%) probes were “unfavorable,” associated with higher
risk of recurrence when methylated (HR ranging from 2.45
to 517.82 on univariable Cox regression with associated
P < 0.001).
There were 2332 probes annotated to 294 genes
with at least 5 probes represented per gene. Of these
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Fig. 3 Frequency of copy number alterations across the genome stratified in risk groups according to the methylome-based predictor. Groups
correspond to same groups seen in Fig. 2.
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Fig. 4 Survival analysis of all WHO grade I (A), WHO grade II (B) and WHO grade III (C) tumors in all 3 validation cohorts stratified by methylationbased predictor risk groups.

(Supplementary Table 9), only 68 of 2332 probes (2.9%)
were found to be “favorable” (associated with lower recurrence risk when methylated, HR ranging from 0.008
to 0.252 on univariable Cox regression with associated
P < 0.001). The remaining 2265 probes (97.1%) were found
to be “unfavorable,” associated with greater recurrence
risk (associated with higher recurrence risk when methylated, HR ranging from 2.95 to 517.82 on univariable Cox
regression with associated P < 0.001). Functional annotation clustering of these 2265 “unfavorable” probes revealed that homeobox (enrichment score = 54.33) and
T-box (enrichment score = 4.12) were highly significant redundant functional clusters (Supplementary Fig. 3). Gene
expression analysis of the homeobox family of genes and
T-box genes for which methylation data were also available demonstrated that although these genes were relatively hypermethylated in recurrence-prone tumors, they

were either upregulated or non-differentially expressed
(Supplementary Table 10).

Validation and Clinical Utility of a Meningioma
Recurrence Score
To generate and validate a meningioma recurrence score
that could be translated to the clinic, we developed a
nomogram to predict 5-year RFS that incorporated the
validated 5-year methylome-based predictor with established prognostic covariates (WHO grade and extent of
resection) using samples from the training cohort and
second validation cohort (Fig. 5). Validation of the nomogram using the first validation cohort and third validation
cohort independently as well as both validation cohorts
combined demonstrated greater predictive performance
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of the nomogram with methylome predictor included
compared with a nomogram using clinical factors (WHO
grade and extent of resection) alone (ΔAUC = 0.24, 95% CI:
0.19–0.28; ΔAUC = 0.26, 95% CI: 0.22–0.31; ΔAUC = 0.25,
95% CI: 0.22–0.27, respectively; Fig. 5). The discriminative
power of the meningioma recurrence score was approximately 82% in combined validation cohorts (AUC = 0.82,
95% CI: 0.76–0.87). The performances of the models using
external validation and internal validation approaches
were similar (Supplementary Fig. 7). The highest proportion of allottable points given in the nomogram is based on
probabilities from the methylome-based predictor, again
suggesting that the methylome predictor has greater importance in determining recurrence risk in meningiomas
compared with established clinical factors. Calibration and
Kaplan–Meier survival analysis of the meningioma recurrence score clearly stratify patients with high risk and low
risk for 5-year recurrence (HR 7.7, 95% CI: 5.3–11.1, P < 0.001;
Fig. 6). Interestingly, while histologic grades II and III are
meant to predict high recurrence risk, we find that the lowrisk group in total contains 39 grade II tumors (34.5% of the
grade II tumors) and 4 grade III tumors (8.3% of the grade
III tumors). Conversely, while a WHO grade I designation is
meant to convey a low risk of recurrence, there were 35
(21.2%) patients with grade I tumors in the high-risk group.
These results indicate refinement of risk estimate by the
nomogram relative to current classification standards.To facilitate unrestricted global dissemination, we have created
a freely available online calculator of the meningioma

recurrence score at: https://meningiomas.shinyapps.io/
meningioma_recurrence_score_online_calculator/.
Details on imputations for the online calculator can be
found in the Supplementary Methods, and case examples
demonstrating the power of personalized predictions are
detailed in Supplementary Figures 8–10.

Discussion
In this multicenter study, we demonstrated the transformative utility of integrating clinical and molecular factors
for use beyond simple classification into the realm of
individualized prognostication in neuro-oncology. Our
methylome-based predictor was more reliably able to predict early (5 y) RFS in comparison with histologic grading
and was associated with RFS independent of established
clinical and molecular factors. Combining the methylome
predictor with established prognostic clinical factors (WHO
grade and extent of resection) in a meningioma recurrence score refined prognostication for individual patients
with meningiomas beyond established prognostic clinical
and molecular factors with therapeutic implications for
individualizing decision making regarding the need for adjuvant therapy after surgery in meningiomas.
Although WHO grade is associated with recurrence in
populations of meningioma patients and is currently used
to guide therapy, the clear within-grade variation for risk
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of recurrence and interrater variability makes it challenging
to rely on tumor grade alone to predict recurrence and
guide postoperative management decisions for individual
patients. As a manifestation of this imprecision, some
patients with biologically aggressive tumors may be inappropriately subsumed within the group of histologically
benign tumors. With current standard of care, it is thought
that up-front treatment with adjuvant radiation therapy
after surgical resection offers the best chance to delay recurrence, and therefore some patients are not appropriately selected for adjuvant treatment with standard-of-care
approaches.3,4 Conversely, there are also some patients
with histologically defined intermediate or higher-grade
tumors that in fact harbor indolent tumor behavior. Such
patients may be receiving adjuvant radiation therapy in the
absence of a defined need. Radiation, even when optimized
to minimize adverse effects, still carries the risk for adverse

radiation effects such as reactive inflammation, vasculitis,
and necrosis, all of which have sequelae on patient cognition and quality of life.5 There is a clear need for a more
refined predictor of recurrence patterns for individual
patients with meningiomas beyond simple classifications,
so that the decision for adjuvant therapy, radiotherapy, or
otherwise can be appropriately selected and personalized
for patients.
The burden of chromosomal alterations have repeatedly been shown to be one of the most important prognostic molecular alterations in meningioma.11,17,22 Similar
to others,11,22 we found recurrent alterations in 1p, 4p, 6q,
10q, 14q, and 18q in a subset of meningiomas that were
enriched in a higher risk group. However, using a previously published copy number score designed to identify
meningiomas with high recurrence risk,17 we found that
the burden of copy number alteration was not an independent predictor of recurrence once adjusted for methylation signature. Similarly, although TERT promoter
mutations are known to be enriched in more aggressive
meningiomas,10 our analysis demonstrated that TERT promoter mutation was not independently associated with
RFS on multivariable analysis with the 5-year methylome
predictor included in the model. Taken together, these
results suggest that our 5-year methylome predictor can
provide prognostic information beyond previously established molecular factors in meningioma.
Probes included in the predictor were selected based
on correlations of either hypo- or hypermethylated
status with respect to RFS. Interestingly, the distribution
of these probes was not random, either with respect
to methylation status or with respect to association
with known genes. The majority (over 86%) of our included probes were all associated with unfavorable RFS
when hypermethylated. This suggests that in general,
hypermethylation of a set of CpG sites in meningioma
correlates with clinical aggressiveness. For example,
hypermethylation of the homeobox and T-box families
of genes were found to be highly overrepresented in
the set of relevant probes, suggesting possible involvement of this class of developmental factors in the clinical behavior of meningioma, which requires further
validation.
To generate a tool that could be used by clinicians
to capture the heterogeneity in recurrence risk in
meningiomas, we established a 5-year meningioma recurrence score that combined our validated methylomebased predictor with well-established prognostic clinical
factors (WHO grade and extent of resection). The performance of our meningioma recurrence score was
improved with the methylome-based predictor included
in the nomogram (ΔAUC = 0.25, 95% CI: 0.22–0.27), and
the overall discrimination of our nomogram was high
(AUC ~82% in 2 independent cohorts). The construction
(and evaluation) of our nomogram meets the standards
of reporting on nomograms in oncology and is one of
the few to demonstrate robust evaluation using multiple independent validation cohorts.23 Now that we have
demonstrated that our tools are robustly validated, we
are well positioned to prospectively validate the use of
our tools to demonstrate efficacy with adjuvant therapy
strategies in high-risk patients.24 Our meningioma
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recurrence score informs both patients and clinicians
about individualized risk of recurrence and can be used to
guide clinicians regarding the need for adjuvant therapy
and/or close clinical follow-up.
Our study has some limitations. First, although we
have identified a group of probes with distinct epigenetic
changes that in combination are predictive of recurrence
risk in meningiomas for individual patients, it is unclear
whether these changes may be conferring variant behavioral phenotypes or whether they are a surrogate for
general cellular dysregulation. Nevertheless, the set of
highly refined and selected probes in our predictor are
enriched to be located on promoters of CpG islands where
aberrant DNA methylation has clearly been linked to carcinogenesis.25 The correlation of methylation with gene expression in our study was exploratory and would benefit
from additional investigation with matched epigenetic and
transcriptomic analysis in the same samples. Moreover,
although each institution conformed to a common definition for tumor recurrence and time to recurrence, there
is no universally standardized definition of recurrence
in meningiomas. The Response Assessment in NeuroOncology guidelines may offer an avenue for standardized
definition of recurrence to be collected on meningiomas in
future clinical trials, which will help with communication
across different centers and may also help with further
model refinement.26
Our predictor has been designed and validated such
that it can be applied to data from fresh frozen or paraffin embedded tissues using the current commonly used
standard platform for genome-wide DNA methylation profiling, facilitating immediate adoption into clinical practice. Our newly developed and retrospectively validated
meningioma recurrence score combines both methylome
and clinical factors and can be freely used by clinicians to
personalize decision making regarding postoperative management of the most common primary intracranial brain
tumor via a web-based interface.
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